FENNEC PHARMACEUTICALS INC. Current Liabilities
FENNEC PHARMACEUTICALS INC. (FENC) had Current Liabilities of $12.39 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Liabilities, Current $12.39M.
- 2026-03-31: Liabilities, Current $9.59M.
- 2025-12-31: Liabilities, Current $10.52M.
- 2025-09-30: Liabilities, Current $9.81M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $12.39M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $9.59M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $10.52M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $9.81M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $8.41M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $8.37M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $6.92M 10-K · filed 2026-03-27 |
| 2024-09-30 | $7.43M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $7.75M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $9.84M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $7.55M 10-K · filed 2025-03-26 |
| 2023-09-30 | $3.91M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $3.78M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $4.02M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.61M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.93M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.04M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $2.14M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.65M 10-K · filed 2023-03-29 |
| 2021-09-30 | $2.01M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $848.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $2.89M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $2.35M 10-K · filed 2022-02-28 |
| 2020-09-30 | $2.88M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $3.19M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.91M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $2.27M 10-K · filed 2021-03-30 |
| 2019-09-30 | $905.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.35M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.45M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $1.64M 10-K · filed 2020-02-14 |
| 2018-09-30 | $2.08M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $847.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $1.17M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $1.64M 10-K · filed 2019-03-15 |
| 2017-09-30 | $1.03M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $580.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $427.00K 10-Q · filed 2017-05-12 |
| 2016-12-31 | $402.00K 10-K · filed 2018-03-28 |
| 2016-09-30 | $360.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $451.00K 10-Q · filed 2016-08-12 |
| 2016-03-31 | $345.00K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $471.00K 10-K · filed 2017-03-29 |
| 2015-09-30 | $431.00K 10-Q · filed 2015-11-12 |
| 2015-06-30 | $759.00K 10-Q · filed 2015-08-11 |
| 2015-03-31 | $1.12M 10-Q · filed 2015-05-15 |
| 2014-12-31 | $1.76M 10-K · filed 2016-03-28 |
| 2014-09-30 | $3.90M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $5.71M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $5.73M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $3.21M 10-K · filed 2015-03-31 |
| 2013-03-31 | $11.00M 10-Q · filed 2013-05-13 |
| 2012-12-31 | $7.32M 10-K · filed 2014-03-31 |
| 2011-12-31 | $5.47M 10-K · filed 2013-04-01 |
| 2010-12-31 | $10.92M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |